TheREx team - Experimental Recombinant Therapy - is organized along the following lines:

- rational design of therapeutic proteins and vectors
- interactions host-pathogen and molecular bases of chronic granulomatous disease
- hematopoietic stem cells and myelodysplasia.

These complementary therapeutic approaches are reinforced by capacities in preformulation and formulation and by a plateforme for precocious phase clinical trials in oncology and hematology.
Our approaches in the field of ‘health technologies’ allow the development of innovative therapy in enzymopathies, hemopathies, and anti-tumor or anti-infectious immunotherapy.

The knowhow of the team is valorized through two startups:

- SYNTHELIS: production of membrane proteins
- APCure: bacterial vectors for immunotherapy

Laboratoire TIMC-IMAG, Domaine de la Merci, 38706 La Tronche Cedex

Grenoble INP
Mentions Légales